Study finds substantial MRSP burden in pyodermic dogs in Asia: full analysis

Version 2

Methicillin-resistant Staphylococcus pseudintermedius is no longer a fringe finding in canine pyoderma in Asia, according to a new systematic review and meta-analysis in Veterinary Research Communications. Reviewing studies published between 2015 and 2024, the authors estimated a pooled prevalence of 30.7% for MRSP in pyodermic dogs, slightly above the 27.9% pooled prevalence for methicillin-susceptible S. pseudintermedius (MSSP). The review adds weight to a growing concern in small animal dermatology: resistant S. pseudintermedius is common enough that it should shape routine diagnostic and treatment decisions, not just referral-level thinking. (link.springer.com)

The study comes as antimicrobial stewardship guidance in canine dermatology has become more explicit. In 2025, ISCAID published updated canine pyoderma guidelines stating that topical antimicrobial therapy alone is the treatment of choice for surface and superficial pyoderma, while systemic antimicrobials should be reserved for deep pyoderma or cases where topical treatment is not effective or feasible. The guidelines also recommend bacterial culture and antimicrobial susceptibility testing whenever systemic therapy is planned, and they emphasize that pyoderma is always secondary to an underlying cause that needs to be addressed to prevent recurrence. (amrvetcollective.com)

Methodologically, the new review followed PRISMA guidance and pulled studies from Scopus, PubMed, Web of Science, and Google. Only cross-sectional studies from Asian countries that used disk diffusion susceptibility testing were included, a choice the authors said was intended to improve consistency across studies. Fifteen studies met inclusion criteria, and the authors rated their overall methodological quality as moderate. The tradeoff is that the pooled estimates came with substantial heterogeneity, with I² values above 90% for both MSSP and MRSP prevalence, suggesting the burden likely varies meaningfully by country, practice setting, and testing approach. (link.springer.com)

On the susceptibility side, the paper offers a practical snapshot, with caveats. Among MSSP isolates, the lowest pooled resistance was reported for amoxicillin-clavulanic acid at 2.6%, oxacillin at 2.7%, and cotrimoxazole at 4.1%, while penicillin and ampicillin showed the highest resistance in that group. For MRSP, the paper highlights higher resistance across multiple drugs, including clindamycin at 26%. The authors also found a pooled mecA prevalence of 11.9% among MRSP isolates in the subset of studies that reported the gene, although that estimate was based on just five studies and also showed high heterogeneity. (link.springer.com)

That aligns with broader clinical guidance. Merck Veterinary Manual notes that S. pseudintermedius is the most common pathogen in canine pyoderma, that empiric use of penicillin, ampicillin, and amoxicillin should be avoided because of beta-lactamase production, and that treatment has become more challenging with the spread of methicillin-resistant and multidrug-resistant staphylococci. ISCAID’s guidance goes further, arguing that cytology should be performed before antimicrobials are used and that topical therapy can help reduce reliance on systemic agents while remaining effective against both methicillin-susceptible and methicillin-resistant staphylococci. (merckvetmanual.com)

For veterinary teams, the bigger takeaway isn’t just that MRSP is prevalent. It’s that canine pyoderma management is moving toward a more disciplined workflow: confirm infection cytologically, use topical therapy first for surface and superficial disease, culture before systemic treatment when possible, and investigate the allergic, parasitic, endocrine, conformational, or other primary drivers behind recurrence. In practices serving pet parents who expect quick antibiotic treatment for every flare, data like these may help support more careful conversations about why culture, follow-up, and underlying disease control matter. (amrvetcollective.com)

There are limits to how far clinicians should generalize the new meta-analysis. The included studies spanned multiple countries and years, used only disk diffusion methods, and showed strong between-study variability. The paper is best read as a regional signal, not a substitute for local antibiograms or case-specific culture results. Even so, the message is hard to miss: in at least parts of Asia, MRSP appears common enough that routine empiric systemic prescribing deserves renewed scrutiny. (link.springer.com)

What to watch: The next step will be whether these findings feed into country-level stewardship efforts, local susceptibility surveillance, and more widespread adoption of topical-first pyoderma protocols in general practice and referral dermatology. (pmc.ncbi.nlm.nih.gov)